you'll hear MORE controversy about using pioglitazone (Actos) for type 2 diabetes

October 2012

New generics plus bladder cancer concerns mean you'll hear MORE controversy about using pioglitazone (Actos) for type 2 diabetes.

Actos is one of the top 25 prescribed drugs in the U.S...and lower prices for the generic could tempt more prescribers to use it.

But some clinicians are reluctant to use it due to growing concerns about bladder cancer.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Hypertension debate about when to start drugs in patients with MILD hypertension
STIs Oral cefixime is no longer first-line for gonorrhea
Diabetes you'll hear MORE controversy about using pioglitazone (Actos) for type 2 diabetes
Infectious Diseases This will be the worst year yet for West Nile virus
Vaccines New virus strains in the 2012-2013 influenza vaccine
Statins whether statins increase the risk of cataracts
Overactive Bladder Myrbetriq (meer-BEH-trick, mirabegron) for overactive bladder
Respiratory & Allergy The new OTC bronchodilator Asthmanefrin (racepinephrine) will be promoted as an alternative to Primatene Mist (epinephrine)
Respiratory & Allergy whether inhaled corticosteroids inhibit growth in kids or increase fracture risk in seniors
Antipsychotics whether it makes sense to use more than one antipsychotic for schizophrenia
Depression more emphasis on treating depression in cardiac patients
Substance Use Disorder Patients are abusing Suboxone (buprenorphine/naloxone) tabs
Hepatitis C hepatitis C testing for ALL baby boomers